$800.00 $700.00

Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d’Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in activation and dysregulation of the gene’s expression and signaling which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines and demonstrated antitumor activity in mice bearing tumor xenografts that expressed echinoderm microtubule-associated protein-like 4 (EML4)- or nucleophosmin (NPM)-ALK fusion proteins or c-Met.

Crizonix (Crizotinib)


Product Description: Crizonix (Crizotinib) is a kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or ROS 1 positive. Crizotinib is the first FDA-approved bioma rker-driven therapy for both ALK positive and ROS1-positive metastatic NSCLC. It is the only FDA approved drug for ROS 1 positive NSCLC.

Indication: CRIZONIX i is indicated for the first-line treatment of adults with ALK-positive advanced NSCLC and for the treatment of adults with previously treated ALK-positive advanced NSCLC  & ROS1 (+) NSCLC. Crizotinib is an ALK and ROS1 (c-ros oncogene 1, receptor tyrosine kinase) inhibitor.

Product Name : Crizonix
Generic Name : Crizotinib
Formulation : Capsule
Available size : 28’s and 60s
Strengths : 250mg

Categories: Oncology, Lung Cancer

Company Name: Beacon Pharmaceuticals Ltd


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

You may also like…

  • Sale! Crizocent


    Anti cancer $800.00 $700.00
    Rated 0 out of 5